ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer

References

• Massard C, Fizazi K. Targeting continued androgen receptor signalling in prostate cancer. Clin Cancer Res 2011;17:3876-83
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer. Version 2, 2014. Available from: www.nccn.org/professionals/physician_gls/f_guidelines.asp [Last accessed 11 September 2014]
   Google Scholar
• Horwich A, Hugosson J, de Reijke T, et al. Prostate cancer: ESMO Consensus Conference Guidelines 2012. Ann Oncol 2013;24:1141-62
   PubMed Web of Science ®Google Scholar
• Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008;68:4447-54
   PubMed Web of Science ®Google Scholar
• Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66:2815-25
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Nakazawa M, Luo J. Resistance to androgen-pathway drugs in prostate cancer. N Engl J Med 2014;371:1028-38
   PubMed Web of Science ®Google Scholar
• Shafi AA, Yen AE, Weigel NL. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Pharmacol Ther 2013;140:223-38
   PubMed Web of Science ®Google Scholar
• Mostaghel EA, Marck BT, Plymate SR, et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 2011;17:5913-25
   PubMed Web of Science ®Google Scholar
• de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005
   PubMed Web of Science ®Google Scholar
• Fizazi K, Scher HI, Molina A, et al. COU-AA-301 Investigators. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012;13:983-92
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, et al. AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-97
   PubMed Web of Science ®Google Scholar
• Beer TM, Armstrong AJ, Rathkopf DE, et al. PREVAIL Investigators. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371:424-33
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015;16:152-60
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22
   PubMed Web of Science ®Google Scholar
• de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147-54
   PubMed Web of Science ®Google Scholar
• Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369:213-23
   PubMed Web of Science ®Google Scholar
• Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377:813-22
   PubMed Web of Science ®Google Scholar
• Amgen. Open-label access protocol of denosumab for subjects with advanced cancer. Available from: http://clinicaltrials.gov/show/NCT01419717
   Google Scholar
• Northwestern University. Zolendronate for the prevention of bone loss in men w/prostate CA on long-term androgen deprivation. Available from: http://clinicaltrials.gov/show/NCT00058188
   Google Scholar
• Janssen Research & Development. Study of abiraterone acetate in patients with advanced prostate cancer. Available from: http://clinicaltrials.gov/show/NCT01217697
   Google Scholar
• Spanish Oncology Genito-Urinary Group. Study of weekly cabazitaxel for advanced prostate cancer. Available from: http://clinicaltrials.gov/show/NCT01518283
   Google Scholar
• Bayer. Radium(223) dichloride (alpharadin) in castration-resistant (hormone-refractory) prostate cancer patients with bone metastases. Available from: http://clinicaltrials.gov/show/NCT01618370
   Google Scholar
• Joseph JD, Lu N, Qian J, et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov 2013;3:1020-9
   PubMed Web of Science ®Google Scholar
• Clegg NJ, Wongvipat J, Joseph JD, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res 2012;72:1494-503
   PubMed Web of Science ®Google Scholar
• Moilanen A, Riikonen R, Oksala R, et al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signalling-directed prostate cancer therapies. Sci Rep 2015;5: 12007
   Web of Science ®Google Scholar
• Fizazi K, Massard C, Bono P, et al. ARADES study group. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncol 2014;15:975-85
   PubMed Web of Science ®Google Scholar
• Massard C, Tammela TLJ, Vjaters E, et al. A study of two ODM-201 formulations with a safety and tolerability extension phase in patients with metastatic chemotherapy-naive castration-resistant prostate cancer (CRPC). J Clin Oncol 2014.32(Suppl 4):abstr 115. Available from: www.orion.fi/globalassets/documents/rd/congress-posters/asco-gu-poster-massard-et-al-2014.pdf?id=955&epslanguage=en
   Google Scholar
• Moilanen A, Riikonen R, Oksala R, et al. ODM-201 - new generation antiandrogen with excellent antiandrogenic and antitumor activity in nonclinical models of CRPC. Eur J Cancer 2013;49(Suppl 2): abstr 2869
   Google Scholar
• Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol 2008;26:1148-59
   PubMed Web of Science ®Google Scholar
• Massard C, Penttinen H, Bono P, et al. Pharmacokinetics, activity, and safety of ODM-201 in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: An open-label phase I trial with long-term extension. J Clin Oncol 2015;33(Suppl 7):abstr 230
   Google Scholar
• Tammela L, Massard C, Bono P, et al. European Urology Supplements. Safety and efficacy of ODM-201 in chemotherapy and CYP17-inhibitor naïve patients: Analysis of data from the ARADES and the ARAFOR trials (abstract 862). Presented at the 29th Annual European Association of Urology Congress, Stockholm, Sweden, 2014. Available from: www.urotoday.com/Prostate-Cancer/eau-2014-poster-safety-and-efficacy-of-odm-201-in-chemotherapy-and-cyp17-inhibitor-naive-patients-analysis-of-data-from-the-arades-and-the-arafor-trials.html
   Google Scholar
• Shore ND, Bono P, Massard C, et al. ODM-201 and the central nervous system - A clinical perspective. J Clin Oncol 2014;32(Suppl 4):abstr 275. Available from: http://meetinglibrary.asco.org/content/90517?media=vm
   Google Scholar
• Tombal B. Non-metastatic CRPC and asymptomatic metastatic CRPC: which treatment for which patient? Ann Oncol 2012;23(Suppl 10):x251-8
   PubMed Web of Science ®Google Scholar
• Nelson JB, Love W, Chin JL, et al. Phase 3, randomized, controlled trial of atrasentan in patients with 13nonmetastatic, hormone-refractory prostate cancer. Cancer 2008;113:2478-87
   PubMed Web of Science ®Google Scholar
• Smith MR, Kabbinavar F, Saad F, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005;23:2918-25
   PubMed Web of Science ®Google Scholar
• See comment in PubMed Commons below. Miller K, Moul JW, Gleave M, et al. Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2013;16:187-92
   PubMed Web of Science ®Google Scholar
• Smith MR, Saad F, Oudard S, et al. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol 2013;31:3800-6
   PubMed Web of Science ®Google Scholar
• Anon. Efficacy and safety study of ODM-201 in men with high-risk non-metastatic castration-resistant prostate cancer (ARAMIS). Available from: http://clinicaltrials.gov/ct2/show/NCT02200614
   Google Scholar
• Korpal M, Korn JM, Gao X, et al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov 2013;3:1030-43
   PubMed Web of Science ®Google Scholar
• Danila DC, Morris MJ, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010;28:1496-501
   PubMed Web of Science ®Google Scholar
• Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010;375:1437-46
   PubMed Web of Science ®Google Scholar
• Saad F, de Bono J, Shore N, et al. Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial. Eur Urol 2015;67:223-30
   PubMed Web of Science ®Google Scholar
• Rathkopf DE, Morris MJ, et al. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol 2013;31:3525-30
   PubMed Web of Science ®Google Scholar
• Foster WR, Car BD, Shi H, et al. Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. Prostate 2011;71:480-8
   PubMed Web of Science ®Google Scholar
• Hussain M, Corn PG, Michaelson MD, et al. Prostate Cancer Clinical Trials Consortium, a program of the Department of Defense Prostate Cancer Research Program and the Prostate Cancer Foundation. Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen. Clin Cancer Res 2014;20:4218-27
   PubMed Web of Science ®Google Scholar
• Saad F, Fizazi K, Jinga V, et al. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. Lancet Oncol 2015;16:338-48
   PubMed Web of Science ®Google Scholar
• Fizazi K, Jones R, Oudard S, et al. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. J Clin Oncol 2015;33:7273-31
   Web of Science ®Google Scholar
• Anon. Safety and efficacy study of enzalutamide in patients with non-metastatic castration-resistant prostate cancer (PROSPER). Available from: http://clinicaltrials.gov/ct2/show/NCT02003924
   Google Scholar
• Anon. A study of ARN-509 in men with non-metastatic castration-resistant prostate cancer (SPARTAN). Available from: http://clinicaltrials.gov/ct2/show/NCT01946204
   Google Scholar
• Sweeney C, Chen Y-H, Carducci MA, et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. J Clin Oncol 2014;32:5s; Suppl; abstr LBA2
   PubMed Web of Science ®Google Scholar
• Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013;14:149-58
   PubMed Web of Science ®Google Scholar
• Loriot Y, Bianchini D, Ileana E, et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol 2013;24:1807-12
   PubMed Web of Science ®Google Scholar
• Mezynski J, Pezaro C, Bianchini D, et al. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol 2012;23:2943-7
   PubMed Web of Science ®Google Scholar
• de Bono JS, Smith MR, Saad F, et al. Response to taxane chemotherapy as first subsequent therapy after abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post-hoc analysis of COU-AA-302. J Clin Oncol 2015;33(Suppl 7):abstr 184
   Google Scholar
• Noonan KL, North S, Bitting RL, et al. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol 2013;24:1802-7
   PubMed Web of Science ®Google Scholar
• Schweizer MT, Zhou XC, Wang H, et al. The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer. Eur Urol 2014;66:646-52
   PubMed Web of Science ®Google Scholar
• Al Nakouzi N, Le Moulec S, Albigès L, et al. Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol 2014;68(2):228-35
   PubMed Web of Science ®Google Scholar
• Anon. Sequencing abiraterone and enzalutamide in mCRPC. Available from: http://clinicaltrials.gov/ct2/show/NCT02125357
   Google Scholar
• Anon. A registry to observe the treatment of prostate cancer under routine medical care. Available from: http://clinicaltrials.gov/ct2/show/NCT02236637
   Google Scholar
• Anon. Enzalutamide with or without abiraterone acetate and prednisone in treating patients with castration-resistant metastatic prostate cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT01949337
   Google Scholar
• Anon. Radium-223 dichloride and abiraterone acetate compared to placebo and abiraterone acetate for men with cancer of the prostate when medical or surgical castration does not work and when the cancer has spread to the bone, has not been treated with chemotherapy and is causing no or only mild symptoms (ERA 223). Available from: http://clinicaltrials.gov/ct2/show/NCT02043678
   Google Scholar
• Anon. Phase III Radium 223 mCRPC-PEACE III. Available from: http://clinicaltrials.gov/ct2/show/NCT02194842
   Google Scholar
• Anon. Abiraterone acetate with or without LHRH-therapy in men with progressive chemotherapy-naïve CRPC. Available from: https://clinicaltrials.gov/ct2/show/NCT02077634
   Google Scholar
• Fizazi K, Abrahamsson PA, Ahlgren G, et al. Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: introducing the prostate cancer consortium in Europe. Eur Urol 2014;67:904-12
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Molina A, Li J, et al. Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. J Clin Oncol 2013;31:2791-8
   PubMed Web of Science ®Google Scholar
• Attard G, de Bono JS, Logothetis CJ, et al. Improvements in radiographic progression-free survival stratified by ERG gene status in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate. Clin Cancer Res 2015;21:1621-7
   PubMed Web of Science ®Google Scholar
• Morris MJ, Molina A, Small EJ, et al. Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results. J Clin Oncol 2015;33:1356
   PubMed Web of Science ®Google Scholar
• Danila DC, Fleisher M, Scher HI. Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res 2011;17:3903-12
   PubMed Web of Science ®Google Scholar
• Gillessen S, Omlin A, Attard G, et al. Management of patients with advanced prostate cancer: Recommendations of the St. Gallen Advanced Prostate Cancer Consensus Conference (APCCC). Ann Oncol 2015; In Press
   Web of Science ®Google Scholar